BioCardia (BCDA) Net Cash Flow (2010 - 2026)

BioCardia (BCDA) has reported Net Cash Flow for 16 consecutive years, with $3.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 10112.9% year-over-year to $3.2 million in Q2 2026; TTM through Jun 2026 was $3.1 million, a 811.34% increase from a year earlier, with the FY2025 full-year figure at $125000.0, down 90.14% from the prior year.
• Net Cash Flow was $3.2 million for Q2 2026 at BioCardia, up from -$1.5 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $4.3 million in Q3 2025 and troughed at -$2.9 million in Q1 2022.
• A 5-year average of -$486388.9 and a median of -$1.0 million in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow tumbled 3196.84% in 2022 and surged 10112.9% in 2026, its largest moves.
• Over 5 years, Net Cash Flow stood at $696000.0 in 2022, then tumbled by 205.17% to -$732000.0 in 2023, then sank by 249.59% to -$2.6 million in 2024, then slipped by 9.07% to -$2.8 million in 2025, then surged by 213.44% to $3.2 million in 2026.
• The last three Net Cash Flow figures came in at $3.2 million (Q2 2026), -$1.5 million (Q1 2026), and -$2.8 million (Q4 2025), per Business Quant data.